FDA Grants Fast Track to PC14586, Potential Therapy for Specific p53 Mutation

Home / Blog / FDA Grants Fast Track to PC14586, Potential Therapy for Specific p53 Mutation
FDA Grants Fast Track to PC14586, Potential Therapy for Specific p53 Mutation
October 30, 2020October 30, 2020
0

The U.S. Food and Drug Administration (FDA) has granted fast track status to PC14586, PMV Pharmaceuticals’ lead therapeutic candidate for the treatment of patients with locally advanced or metastatic solid tumors, including breast cancer, who have a specific mutation in the gene that encodes the tumor suppressor protein p53. A fast track designation facilitates the development of potential treatments that cater to unmet medical needs in serious conditions. Medication candidates receiving such status may be…

You must be logged in to read/download the full post.

The post FDA Grants Fast Track to PC14586, Potential Therapy for Specific p53 Mutation appeared first on BioNewsFeeds.